Current calls, week 19, 2020
Tips from KI Grants Office about current calls
Swedish and Nordic calls
Network grant within the infection area, knowledge gaps within antimicrobial resistance – Swedish Research Council
This aims to create opportunities for national networks that contribute to better treatment of infections caused by bacteria or fungi by pre-empting and preventing the development and spread of resistance against antibacterial and antifungal medicines. The total budget is SEK 5 million and the grants are worth SEK 600,000 for between one and two years.
Closing date: 26 May 2020
Research time for clinicians within the infection area, resistance to antibacterial and antifungal drugs – Swedish Research Council
This enables clinically active persons to conduct relevant research on a part-time basis within the infection area, focusing on resistance to antibacterial and antifungal drugs. The grant is worth SEK 2 million and covers 12 months of full-time research, allocated over three years.
Closing date: 26 May 2020
Support for short term technical and research/administrative staff exchange at the Rockefeller University, USA
The Rockefeller University and Karolinska Institutet announce the availability of funds for exchange positions that will allow KI researchers, PhD students, Master students and other individuals to work in laboratories, resource centers, or administrative offices at Rockefeller University, in New York City, New York, USA, for a period of up to 12 weeks.
Closing date: 27 May 2020
Support for a Postdoctoral Fellowship at Rockefeller University, USA
Rockefeller University announces the availability of funding for one postdoctoral training position in basic science at Rockefeller University in New York City, New York, USA. Eligible to apply are doctoral students/postgraduate students and postdoctoral investigators.
Closing date: 27 May 2020
Athenapriset – Vinnova
Detta syftar till att lyfta fram klinisk forskning av hög vetenskaplig kvalitet där sjukvård, akademi och näringsliv samarbetar för att utveckla sjukvården. Priset är värt SEK 150,000.
Closing date: 31 May 2020
Forskningsbidrag – Ollie och Elof Ericssons Stiftelse för Vetenskaplig Forskning
Ollie och Elof Ericssons Stiftelse för Vetenskaplig Forskning inbjuder ansökningar om forskningsbidrag. Dessa stöder forskning inom ämnesområdena medicin, teknik och ekonomi. Behöriga att söka är unga, disputerade, självständiga forskare som påbörjat uppbyggnaden av egen forskningsverksamhet. Genomförd postdoc utbildning och därmed institutionsbyte är meriterande.
Closing date: 31 May 2020
Blue Sky Grant for Innovative Cancer Research & Technology 2020 - Cancer Research KI
Cancer Research KI hereby announces up to five project grants in cancer research for well-defined innovative pilot projects that aim to demonstrate proof of principle. The project should be of a "high risk – high reward" type that cannot yet attract funding from conventional funding agencies. The aim should be to obtain proof of principle and thereby provide the basis to obtain other funding. The project should not be a continuation or expansion of already funded projects.
Closing date: 31 May 2020
Translational Seed Funding Grant 2020 – Cancer Research KI
Cancer Research KI hereby announces up to five project grants in cancer research to foster novel collaborations between basic and clinical scientists to address important problems in the area of translational cancer research.
Closing date: 31 May 2020
Apparaturanslag – Parkinson Foundation in Sweden
Dessa möjliggör inköp av medeldyr apparatur eller apparatur som inte är av baskaraktär. Anslag uppgår till SEK 300,000 var.
Closing date: 1 June 2020
Forskningsanslag – Gunvor och Josef Anérs Stiftelse
Gunvor och Josef Anérs stiftelse inbjuder ansökningar om forskningsanslag. Dessa stödjer vetenskaplig forskning med företräde för humanistiska forskningsgrenar. Projekt kan beröra följande områden: Humanistiska och samhällsvetenskapliga forskningsområden, värt minst 15 procent och högst SEK 150,000 av den totala projektsumman; Medicinska forskningsområdet, värt minst 15 procent av den totala projektsumman.
Closing date: 1 June 2020
Etableringsanslag – Jeanssons Stiftelser
Etableringsanslag till yngre forskare, som är i färd med att etablera sin egen forskargrupp. Sökande bör ha någon form av institutionsanknuten tjänst och ha disputerat 2014 eller senare om ej särskilda skäl föreligger. Ange datum för disputation. Sökande kan beviljas årligt anslag vid två tillfällen, men ej mera. Sökande måste ange om det gäller fortsättningsanslag. För att erhålla ett fortsättningsanslag krävs tillfredsställande rapport om aktuell aktivitet. Anslag bör ej sökas för egen lön. Anslag ges företrädesvis till sökande som ännu ej beviljats större anslag som täcker fleråriga kostnader för lön och drift.
Closing date: 17 June 2020
Collaborative Call for Breast Cancer Applications 2020 – Karolinska Institutet and Mayo Clinic Cancer Center
The Mayo Clinic Cancer Center and Karolinska Institutet are pleased to announce the 2020 Request for Applications (RFA) within the area of breast cancer with a submission deadline of July 15th, 2020. Having created a unique network, Mayo Clinic Cancer Center and Karolinska Institutet are in an excellent position to leverage this relationship to make a global impact on cancer through research focusing on the diagnosis, prevention, or treatment of breast cancer.
Closing date: 15 July 2020
Horizon prize for early warning for epidemics - Horizon 2020: European Innovation Council
The European Innovation Council invites proposals for its H2020 Horizon prize for early warning for epidemics. This supports projects that develop a scalable, reliable, cost-effective prototype early warning system to forecast and monitor vector borne diseases in order to contribute to the prevention of outbreaks, mitigating their impact at local, regional and global scales and providing support to existing elimination efforts. The prototype early warning system should encompass innovative technological solutions integrating big data derived from the Earth observation domain. The solution must be demonstrated at local level, taking into account any relevant societal factors in the chosen geographical area.
Deadline for registration of interest: 31 May 2020
Closing date for submission: 1 September 2020
Advanced research grants in amyotrophic lateral sclerosis - Radala Foundation for ALS Research
The Radala Foundation invites applications for its advanced research grants in amyotrophic lateral sclerosis (ALS). These support potentially ground-breaking, high-risk projects in basic research in ALS. Grants are for studies of the understanding of the basic causes of the disease, and clinically related projects for patient care are not eligible. Established, leading PIs may apply. They are expected to be active researchers and have a track-record of significant research achievements in the last 10 years. Research must be conducted in a public or private research organisation. There are no geographical limitations.
Closing date: 30 June 2020
Future topics – Innovative medicines initiative - IMI
IMI2 – Calls 22 and 23
Planned to be launched on 23rd of June 2020 (this date is indicative and may change)
The following topics are under consideration for inclusion in the next IMI Calls for proposals. These topics are now at an advanced stage of development and we hope that these drafts will allow potential applicants to start working actively on proposals and forming consortia. Draft topic texts are subject to consultations involving IMI's States Representatives Group, Scientific Committee, and the European Commission. They must also be approved by the IMI Governing Board. Depending on the results of the consultations and approval process, the final topic text may differ significantly from the draft versions initially published here, and applicants should always base their proposals on the final, approved topic texts which will be published when the Call is officially launched. Furthermore, although it is unlikely at this stage, it is possible that a draft topic may be dropped entirely.
- Returning clinical trial data to study participants within a GDPR compliant and approved framework
- Modelling the impact of monoclonal antibodies and vaccines on the reduction of antimicrobial resistance
This topic is part of IMI’s Antimicrobial Resistance (AMR) Accelerator programme.
- A platform for accelerating biomarker discovery and validation to support therapeutics development for neurodegenerative diseases
- Optimal treatment for patients with solid tumours in Europe through artificial intelligence
- Shortening the path to rare disease diagnosis by using new born genetic screening and digital technologies
- Behavioural model of factors affecting patient adherence
- Restricted Call to maximise impact of IMI2 JU objectives and scientific priorities - Updated on 21 April to include list of eligible consortia
Marie Skłodowska Curie Actions Individual Fellowships 2020 - Call and Bootcamp at KI
MSCA-IF are postdoc fellowships, for a project within Europe with a 2-year European Fellowship, or outside Europe (2 years) with a mandatory 1-year return phase to Europe with the 3-year Global Fellowship.
Applicants are fellows with an identified PI. The fellows should have a PhD degree or equivalent four years of full-time research experience by the time of the deadline 2020-09-09.
The Call is open and will close on September 9th 2020.
If you are applying for the MSCA-Individual Fellowships, Grants Office offers a Bootcamp to help with your proposal for those who apply with KI as Host Organisation. The Bootcamp is three days in total, with Day 1 set for 11th June. Dates for Day 2-3 during mid August will be announced later.
Federal Funding agencies
Large scale mapping and/or molecular profiling of ensembles and/or cell-types mediating opioid action in the rodent brain (R01 - Clinical Trial Not Allowed): NIH
This funding opportunity announcement aims to support research that employs innovative scalable technologies to identify, map, and profile cellular ensembles and/or cell-types that produce and/or respond to opioids or that are engaged during different stages of opioid use (acute, chronic, withdrawal, abstinence, relapse). Emphasis is on approaches that enable high-throughput single-cell resolution mapping, anatomical characterization and/or molecular profiling of cells identified as targets of, or as primary sources of opioids in the brain.
Applications which lack the required components below will be considered inappropriate for the FOA and will not be awarded. In order to be considered for an award, the major thrust of the proposal MUST investigate opioid exposure in an appropriate rodent model. Any opioid may be investigated (endogenous peptides, morphine, heroin, fentanyl, etc.). Acceptable exposure regimens include: acute vs chronic, experimenter vs self-administered, acute early exposure, long access, withdrawal, and relapse. In addition, the major thrust of appropriate applications MUST focus on at least one of the following
- Approaches to identify and characterize molecularly-defined cell ensembles producing or responding to opioids in the CNS. These approaches may include measures of connectivity, activity, drug action, and/or single-cell resolution transcriptomic-based profiling.
- Single cell resolution transcriptomic-based profiling in brain regions considered a priori to be involved in response to opioid exposure (e.g. NAc, PFC)
Closing date: October 30, 2020. All applications are due by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement (FOA): PAR-20-182.
Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R01 Clinical Trial Not Allowed): NIH
Applications will be accepted on a rolling basis, beginning on 04/30/2020.
The purpose of this Funding Opportunity Announcement (FOA) is to provide an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). Areas of high priority are described in this FOA (follow link below). All NIAID-funded researchers are expected to share research data to enhance the rigor and reproducibility of research results and secondary use per the NIAID Data Sharing Guideline at https://www.niaid.nih.gov/research/data-sharing-and-release-guidelines,as appropriate and consistent with achieving the goals of the program. Please get in contact with GO already in the planning phase if you are planning to use human data in your project (email@example.com).
Closing date: Applications will be accepted on a rolling basis, beginning on 04/30/2020. All applications are due by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement (FOA): PAR-20-178 (R01), PAR-20-177 (R21)
Research to Reduce Morbidity and Improve Care for Pediatric, and Adolescent and Young Adult (AYA) Cancer Survivors (R01 Clinical Trial Optional): NIH
Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications describing research focused on improving care and health-related quality of life for childhood, and adolescent and young adult (AYA) cancer survivors. Specifically, this FOA solicits mechanistic, observational, and intervention applications that focus on six key domains: (1) disparities in survivor outcomes; (2) barriers to follow-up care (e.g. access, adherence); (3) impact of familial, socioeconomic, and other environmental factors on survivor outcomes; (4) indicators for long-term follow-up needs related to risk for late effects, recurrence, and subsequent cancers; (5) risk factors and predictors of late/long-term effects of cancer treatment; and (6) development of targeted interventions to reduce the burden of cancer for pediatric/AYA survivors..
Closing date: October 1, 2020 , July 30, 2021. All applications are due by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement (FOA): RFA-CA-20-027 (R01), RFA-CA-20-028 (R21)
Global research award, American Society of Hematology, US
The ASH Global Research Award was designed to support future international scientific leaders, increase hematology capacity, and nurture global collaboration. The award is intended to support hematologists between completion of training and the establishment of their independent careers.
The following types of projects will be considered:
- Hematology research, including basic, translational, patient-oriented, and outcomes-based research
- Requests for training at other institutions by trainees or early-career investigators, pilot studies, collaborative projects, and other proposals for career development
Examples of potential projects include, but are not limited to:
- Projects advancing the diagnostic capabilities or therapeutic care delivery of hematological illnesses in developing regions
- Projects addressing hematological illnesses of high incidence and impact in the applicant’s home region
- Projects incorporating cross-disciplinary collaborations aimed at enhancing regional scientific and care capabilities for hematologic illnesses
- Projects enhancing career development of individuals who will play future leadership roles in regional scientific and care delivery roles for hematologic illnesses
The Global Research Award requires that all applicants have a local mentor and a global mentor. The global mentor must be in a region or country outside of the applicant’s region or country of residence. One of the two mentors must be an ASH Active or International member.
Budget: Project length may vary from six months to three years depending on the proposed project need. For projects of one year or less, applicants may request up to USD 100,000. For projects of more than one year, applicants may request up to USD 150,000.
- You have an MD, PhD, or MD-PhD (or its equivalent). At the letter of intent due date:
- MD graduation may be no more than 16 years prior to application, or the applicant may have no more than 10 years of post-doc experience after PhD graduation
- Applicants holding both MD and PhD degrees must be within 16 years of MD graduation
- PhD applicants should have at least one year of experience
- You are or will be an ASH member in good standing at the time of award activation and plan to maintain membership for the duration of the award term. ASH members eligible for this award include:
- Early-career International members
- International Associate members
- Active and Associate members who reside in Mexico and otherwise meet the training and professional experience criteria outlined above
Closing date: Letter of Intent Deadline (Applicants may request assistance with identifying mentors as they complete the LOI. See FOA): August 31, Application Deadline for Invited Applicants: April 15, 2021